CytomX Therapeutics Inc (CTMX) Insider Rachel Humphrey Sells 23,840 Shares
CytomX Therapeutics Inc (NASDAQ:CTMX) insider Rachel Humphrey sold 23,840 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $30.00, for a total value of $715,200.00. Following the completion of the sale, the insider now directly owns 54,074 shares of the company’s stock, valued at $1,622,220. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Shares of CytomX Therapeutics Inc (CTMX) opened at $33.22 on Monday. CytomX Therapeutics Inc has a 12-month low of $12.50 and a 12-month high of $33.50.
A number of equities research analysts recently commented on the company. Zacks Investment Research lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, February 19th. BidaskClub raised CytomX Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 7th. Citigroup assumed coverage on CytomX Therapeutics in a research report on Friday, January 5th. They set a “buy” rating and a $40.00 target price for the company. Finally, ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Three research analysts have rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $32.78.
TRADEMARK VIOLATION WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.watchlistnews.com/cytomx-therapeutics-inc-ctmx-insider-rachel-humphrey-sells-23840-shares/1908546.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.